Treace Medical Concepts, Inc. (NASDAQ:TMCI) Insider Sells $50,650.75 in Stock

Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Rating) insider John T. Treace sold 2,075 shares of the stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $24.41, for a total transaction of $50,650.75. Following the completion of the transaction, the insider now owns 5,539,380 shares of the company’s stock, valued at approximately $135,216,265.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Treace Medical Concepts Trading Down 2.8 %

NASDAQ:TMCI opened at $24.07 on Monday. Treace Medical Concepts, Inc. has a twelve month low of $12.48 and a twelve month high of $26.50. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.77 and a current ratio of 4.41. The company has a 50-day moving average of $23.28 and a 200-day moving average of $22.89.

Treace Medical Concepts (NASDAQ:TMCI – Get Rating) last posted its quarterly earnings data on Tuesday, March 7th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. Treace Medical Concepts had a negative net margin of 30.19% and a negative return on equity of 54.51%. The company had revenue of $49.77 million during the quarter. Equities analysts expect that Treace Medical Concepts, Inc. will post -0.81 earnings per share for the current year.

Institutional Trading of Treace Medical Concepts

A number of hedge funds have recently bought and sold shares of the company. Altshuler Shaham Ltd purchased a new stake in Treace Medical Concepts during the fourth quarter valued at about $25,000. FWL Investment Management LLC purchased a new stake in Treace Medical Concepts during the fourth quarter valued at about $123,000. TD Capital Management LLC purchased a new stake in Treace Medical Concepts during the fourth quarter valued at about $57,000. Summit Partners Public Asset Management LLC lifted its stake in Treace Medical Concepts by 1.7% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 493,213 shares of the company’s stock valued at $11,339,000 after buying an additional 8,127 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Treace Medical Concepts during the fourth quarter valued at about $1,153,000. 46.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TMCI. Morgan Stanley raised their price objective on shares of Treace Medical Concepts from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, March 8th. BTIG Research raised their price objective on shares of Treace Medical Concepts to $29.00 in a research report on Tuesday, November 15th.

About Treace Medical Concepts

(Get Rating)

Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.